The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Covidien Launches Campaign to Increase Awareness of Pregnancy-Related Blood Clots

<p class='bwalignc'> <i>New “1 in 1,000” campaign helps healthcare professionals educate patients about VTE risks </i><br/><i>during pregnancy, delivery and postpartum</i> </p> <p class='bwalignc'> </p>

Wednesday, June 27, 2012

Covidien Launches Campaign to Increase Awareness of Pregnancy-Related Blood Clots07:00 EDT Wednesday, June 27, 2012 WASHINGTON (Business Wire) -- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of its “1 in 1,000” campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world.1 The announcement was made at the 2012 annual meeting of the Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN). “1 in 1,000” refers to the number of women who are likely to experience a potentially life-threatening blood clot during pregnancy, delivery or postpartum. These blood clots, called venous thromboembolism (VTE), encompass both deep vein thrombosis and pulmonary embolism. “The increased incidence of VTE during pregnancy and the peripartum period warrants special consideration and preventive intervention,” said Randall Kuhlmann, MD, PhD, director of the Maternal Fetal Medicine Section and Maternal Fetal Care Center at Children's Hospital of Wisconsin and Froedtert Hospital. “As an obstetrician, it is my job to protect my patients from this preventable disease by facilitating education and following the recommended guidelines for prophylaxis.” Developed in consultation with leading women's health experts, the “1 in 1,000” education and prevention program focuses on empowering healthcare professionals to take action against VTE. The program includes guidelines and materials on how to educate pregnant patients on the risks of VTE and highlights the importance of appropriate VTE risk assessment - as well as prevention protocols at hospitals and health systems. The Association of periOperative Registered Nurses (AORN) awarded its Seal of Recognition for “1 in 1,000” campaign program components. Additional program information and materials can be accessed at www.covidien.com/1in1000. “Research shows that pregnant women are at four to five times' greater risk for developing a potentially life-threatening VTE than non-pregnant women,2” said Stacy Enxing Seng, President, Vascular Therapies, Covidien. “Our goal with this campaign is to help prevent these occurrences by opening the lines of communication between healthcare providers and their patients about the frequency and severity of this condition. Informed discussion, ongoing patient assessment and preventive intervention may help save lives.” In pregnant women, the likelihood of VTE onset heightens during delivery and the immediate postpartum period. Physiologic and anatomic changes during pregnancy increase a woman's risk for VTE,3 and having a Cesarean delivery (C-section) nearly doubles that risk.4 Other risk factors include personal or family history of clotting disorders, pregnancy-induced hypertension, age greater than 35, obesity, race and smoking, among others.5 The American College of Obstetricians and Gynecologists recently issued guidelines recommending prophylaxis and treatment for thromboembolic events in pregnancy, including the placement of pneumatic compression devices for all women undergoing C-sections who are not already receiving another form of thromboprophylaxis.6ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business. References 1. Chang J, Elam-Evans LD, Berg CJ, Herndon J, Flowers L, Seed KA, et al. Pregnancy-related mortality surveillance—United States, 1991–1999. MMWR Surveill Summ 2003; 52:1–8. 2. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697–706. 3. Gordon MC. Maternal physiology. In: Gabbe SG, Niebyl JR and Simpson JL, editors. Obstetrics: normal and problem pregnancies. 5th ed. Philadelphia (PA): Churchill Livingstone; 2007. p. 55–84. 4. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 1996;41:83–6. 5. James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311–5. 6. Thromboembolism in pregnancy. Practice Bulletin No. 123. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011; 118:718–29. Vascular TherapiesDavid T. Young, 508-452-1644Manager, External Communicationsdavid.young@covidien.comorBruce Farmer, 508-452-4372Vice PresidentPublic Relationsbruce.farmer@covidien.comorColeman Lannum, CFA, 508-452-4343Vice PresidentInvestor Relationscole.lannum@covidien.comorTodd Carpenter, 508-452-4363DirectorInvestor Relationstodd.carpenter@covidien.com